Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.39M.
Overvalued
The company’s latest PE is -1.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.84M shares, increasing 6.20% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 227.47K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.10.